Sagent Pharmaceuticals (SGNT) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Sagent Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 3, 2015 7:01 AM ESTCompany Affirms 2015 Full Year Guidance
Allan Oberman Assumes Role of Chief Executive Officer effective September 12, 2015
SCHAUMBURG, Ill., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended September 30, 2015.                                                                                                                                       Third Quarter 2015 and Recent Highlights
Revenue increased 15.1% to $75.2 million driven by base business growth and the October 1, 2014 acquisition of Omega Laboratories Limited (Omega);Gross profit of $24.4 million, or 32.4% of net revenue, inclusive of $0.7 million of non-recurring adjustments;Adjusted EBITDA1Â increased 21% to $8.8 million;Settled zoledronic... More